Overview

Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

Status:
Completed
Trial end date:
2016-05-24
Target enrollment:
Participant gender:
Summary
The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.
Phase:
Phase 3
Details
Lead Sponsor:
Rabin Medical Center
Treatments:
Opicapone